KeyZell is a biopharmaceutical company in the clinical phase, which develops drugs for the treatment of cancer and an innovative artificial intelligence system that aims to be the future of precision medicine in oncology. KeyZell has recently been awarded by the Global Health & Pharma International Life Science Awards 2022 and by the Isaac Peral National Awards for Research, Science and Innovation 2022, awarded by (AEDEEC). In addition, it has been recognized by the British magazine "Health Tech World" as one of the 50 best innovative companies in technology in the health sector in 2022.